Pediatric blood & cancer · 2026
Hypertension in Wilms Tumor at Diagnosis: Proposed Treatment Recommendations Starting From a Bi-Institutional Retrospective Observational Study.
СтатьяНаблюдательное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bondanese Alessandra, Gattuso Giovanna, Hassan Vittoria, Podda Marta Giorgia, Colombo Valeria, Zucchetti Giulia, Novara Chiara, Torchio Francesca, Mauri Lucia, Pizzamiglio Sara, Verderio Paolo, Peruzzi Licia, Montini Giovanni, Fagioli Franca, Massimino Maura, Quarello Paola, Spreafico Filippo
Аннотация
BACKGROUND: Arterial hypertension (AH) is a common clinical finding at the time of Wilms tumor (WT) diagnosis, is often difficult to manage, and is potentially related to acute complications.
METHODS: We retrospectively analyzed 147 patients with newly diagnosed WT treated between January 2010 and December 2023 at two high-volume Italian pediatric oncology centers. Demographic, clinical, treatment, and tumor characteristics were evaluated in relation to the presence of AH.
RESULTS: At WT diagnosis, 75/147 (51%) of patients were hypertensive. Large tumor volume (continuous variable, p = 0.011), advanced tumor stage (p = 0.012), bilateral disease (p = 0.015), and renal vascular involvement (p = 0.004) were significantly associated with AH. Calcium channel blockers were the most frequently used antihypertensive agents, followed by angiotensin converting enzyme inhibitors. Six out of 75 (8%) of patients suffered from secondary complications related to AH.
CONCLUSIONS: We confirmed the high prevalence of AH at WT diagnosis and identified tumor-related factors associated with an increased risk of developing AH. The key elements for the adequate management of these patients include the use of appropriate antihypertensive therapy and proper routine blood pressure screening for all patients with a new WT diagnosis. In the absence of standardized treatment guidelines, we propose recommendations developed through collaboration among pediatric oncologists, cardiologists, and nephrologists.
TRIAL REGISTRATION: EudraCT number 2016-004180-39.
METHODS: We retrospectively analyzed 147 patients with newly diagnosed WT treated between January 2010 and December 2023 at two high-volume Italian pediatric oncology centers. Demographic, clinical, treatment, and tumor characteristics were evaluated in relation to the presence of AH.
RESULTS: At WT diagnosis, 75/147 (51%) of patients were hypertensive. Large tumor volume (continuous variable, p = 0.011), advanced tumor stage (p = 0.012), bilateral disease (p = 0.015), and renal vascular involvement (p = 0.004) were significantly associated with AH. Calcium channel blockers were the most frequently used antihypertensive agents, followed by angiotensin converting enzyme inhibitors. Six out of 75 (8%) of patients suffered from secondary complications related to AH.
CONCLUSIONS: We confirmed the high prevalence of AH at WT diagnosis and identified tumor-related factors associated with an increased risk of developing AH. The key elements for the adequate management of these patients include the use of appropriate antihypertensive therapy and proper routine blood pressure screening for all patients with a new WT diagnosis. In the absence of standardized treatment guidelines, we propose recommendations developed through collaboration among pediatric oncologists, cardiologists, and nephrologists.
TRIAL REGISTRATION: EudraCT number 2016-004180-39.